Funding to stop Candida auris lacking

A high proportion of people who have been diagnosed with C. auris have died


Scientists who work in mycology — the study of fungi — say there is precious little money available to study Candida auris, according to an article on the STAT News website.

Candida auris is making news for its ability to resist multiple antifungal drugs and settle into hospital rooms so persistently it can take renovations to get rid of it.

The head of mycotic diseases at the Centers for Disease Control and Prevention (CDC) acknowledged his field hasn’t attracted the same kind of research dollars as other pathogens.

A high proportion of people who have been diagnosed with C. auris have died — the CDC estimates it’s between 30 percent and 60 percent.

Read the article.



July 16, 2019


Topic Area: Infection Control


Recent Posts

3 Ways to Secure a Healthcare Facility

As workplace violence grows in healthcare, being aware of different security methods can help prevent and address dangerous situations.


Use Cases for Insulated Metal Panels in Healthcare Building Projects

Case study: The UC Medical Center selected IMPs for its ongoing revitalization project.


Memorial Healthcare System Plans Two New Freestanding Emergency Departments

Construction is expected to begin in early 2025 and complete by mid 2026.


Communication Proves to Be Essential Task During Design Phase

Projects go over more smoothly when people are transparent and communicating openly.


Northwest Healthcare Acquires Carbon Health Urgent Care Centers in Arizona

With this acquisition, Northwest Healthcare has more than 80 sites of care.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.